CALCULATE YOUR SIP RETURNS

Stocks To Watch Today on December 2, 2024: HUL, SBI, Bajaj Auto, M&M and More Can be in Focus

02 December 20243 mins read by Angel One
Check out the stocks to watch on December 2, 2024, as they have made a significant announcement, which might affect their share price.
Stocks To Watch Today on December 2, 2024: HUL, SBI, Bajaj Auto, M&M and More Can be in Focus
ShareShare on 1Share on 2Share on 3Share on 4Share on 5

The Indian benchmark indices Sensex and Nifty 50 are expected to start on a positive note amid mixed global cues. Check out a few stocks that might be in focus during the trading session.

  • Hindustan Unilever (HUL)

Hindustan Unilever Limited (HUL) highlighted in its investor presentation that 10 of its brands are well-positioned in the premiumisation segment. The company identified six long-term growth opportunities: premium skincare products for the face, hair, body washes, homecare liquids, condiments, mini meals, and categories like prestige and well-being, which offer high double-digit growth potential.

  • SBI

State Bank of India (SBI) has launched a nationwide campaign aimed at increasing awareness of the importance of activating inoperative accounts. Accounts with no customer transactions for over two years are categorised as inoperative.

  • Bajaj Auto

KTM, the Austrian bike manufacturer, clarified that the judicial restructuring of its parent firm, Pierer Mobility AG, will not impact its business collaborations with Bajaj Auto. This includes the co-developed products for India’s domestic market and selected export markets.

  • Raymond

Raymond Realty, the real estate division of Raymond, plans to go public during the second quarter of FY26. Harmohan Sahni, the CEO of Raymond Realty, confirmed these listing plans.

  • Mahindra & Mahindra (M&M)

M&M announced plans to utilise its existing sales network to market its range of electric vehicles. The company aims to provide customers with all vehicle options under one roof.

  • Biocon

Biocon Biologics Ltd (BBL), a subsidiary of Biocon, secured approval from the US Food and Drug Administration (USFDA) for YESINTEK (Ustekinumab-kfce), a biosimilar to Stelara (Ustekinumab).

Disclaimer: This blog has been written exclusively for educational purposes. The securities mentioned are only examples and not recommendations. It is based on several secondary sources on the internet and is subject to changes. Please consult an expert before making related decisions.

We're Live on WhatsApp! Join our channel for market insights & updates

Open Free Demat Account!

Join our 2 Cr+ happy customers

+91
Enjoy Zero Brokerage on Equity Delivery
4.4 Cr+DOWNLOADS
Enjoy ₹0 Account Opening Charges

Get the link to download the App

Send App Link
Get it on Google PlayDownload on the App Store
Open Free Demat Account!
Join our 2 Cr+ happy customers